Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/21/2021 10/22/2021 10/25/2021 10/26/2021 10/27/2021 Date
96.2(c) 93.98(c) 93.67(c) 94.87(c) 94.17 Last
851 764 812 942 1 669 096 628 647 903 366 Volume
+0.53% -2.31% -0.33% +1.28% -0.74% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 731 M - -
Net income 2021 -493 M - -
Net Debt 2021 1 374 M - -
P/E ratio 2021 -31,8x
Yield 2021 -
Sales 2022 2 090 M - -
Net income 2022 -487 M - -
Net Debt 2022 1 558 M - -
P/E ratio 2022 -34,5x
Yield 2022 -
Capitalization 16 313 M 16 313 M -
EV / Sales 2021 10,2x
EV / Sales 2022 8,55x
Nbr of Employees 4 900
Free-Float 99,2%
More Financials
Company
Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to... 
More about the company
Ratings of Exact Sciences Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about EXACT SCIENCES CORPORATION
10/26New Cologuard« Modeling Data Show Patient Navigation Matters When Reaching Underserved ..
PU
10/25Exact Sciences Corp. Shares Data from Modeling Analyses that Demonstrate Cologuard
CI
10/20TRACKINSIGHT : Cathie’s ARK fleet sails to green waters
TI
10/11EXACT SCIENCES : Hosts Maydm Interns
PU
10/08EXACT SCIENCES : schedules third quarter 2021 earnings call
PR
10/07ONCOCYTE : Names Gisela Paulsen as Operations Chief
MT
10/05INSIDER SELL : Exact Sciences
MT
09/15EXACT SCIENCES : Hires Sales Employees From Pfizer for Cologuard Promotion; Shares Up
MT
09/15Exact Sciences in Talks With Pfizer Amid Cologuard Sales-Force Changes
DJ
09/14Exact Sciences Corporation and National Surgical Adjuvant Breast and Bowel Project Anno..
CI
09/02EXACT SCIENCES : to Present New Oncotype DX Genomic Prostate Score« Test Data and Exhibit ..
PU
09/01EXACT SCIENCES : to participate in September investor conferences
PR
08/30RENALYTIX : Appoints Daniel J. Levangie to its Board of Directors
AQ
08/16EXACT SCIENCES' : Cancer Test Related to Chemo Therapy Recommendations Gets Regulatory App..
MT
08/16EXACT SCIENCES : receives regulatory approval for the Oncotype DX Breast Recurrence Score«..
PR
More news
News in other languages on EXACT SCIENCES CORPORATION
10/20TRACKINSIGHT : La flotte ARK de Cathie Wood naviguent vers la zone verte
10/05VENTE D'INITIÉS : Exact Sciences
09/15Exact Sciences embauche des employés des ventes de Pfizer pour la promotion de Cologuar..
08/09EN DIRECTO DESDE LOS MERCADOS : Sika, ByteDance, Renault, Logitech, PostNL, Aramco, Philip..
08/09Resultados casi perfectos
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | EXAS | US30063P1057 | MarketScreener
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 94,87 $
Average target price 142,35 $
Spread / Average Target 50,1%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors